Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Short Interest Up 1,484.6% in April

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 515,000 shares, a growth of 1,484.6% from the March 31st total of 32,500 shares. Based on an average daily trading volume, of 214,100 shares, the days-to-cover ratio is presently 2.4 days. Currently, 2.8% of the shares of the company are sold short.

Monogram Orthopaedics Trading Up 1.3 %

Shares of MGRM stock traded up $0.03 during trading on Thursday, reaching $2.36. 35,731 shares of the company’s stock traded hands, compared to its average volume of 181,510. The company has a market capitalization of $74.65 million and a P/E ratio of -2.99. The firm’s 50-day moving average is $2.50 and its 200 day moving average is $2.93. Monogram Orthopaedics has a 1 year low of $1.53 and a 1 year high of $48.99.

Monogram Orthopaedics (NASDAQ:MGRM) last announced its quarterly earnings results on Friday, March 15th. The company reported ($0.09) EPS for the quarter. The company had revenue of $0.37 million for the quarter. As a group, sell-side analysts predict that Monogram Orthopaedics will post -0.43 earnings per share for the current fiscal year.

Institutional Trading of Monogram Orthopaedics

An institutional investor recently bought a new position in Monogram Orthopaedics stock. New Harbor Financial Group LLC bought a new position in shares of Monogram Orthopaedics, Inc. (NASDAQ:MGRM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 29,348 shares of the company’s stock, valued at approximately $101,000. New Harbor Financial Group LLC owned 0.09% of Monogram Orthopaedics at the end of the most recent quarter. 0.45% of the stock is owned by institutional investors and hedge funds.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.